Research IV on Pharmacovigilance and Risk Control During Clinical Trials of New Drugs: A Study on Regulatory Requirements for Periodic Safety Report in Clinical Trials

Feng Hongyun, Zhi Huijing, Li Hao, Zhou Lingyun, Shao Ying, Lü Xinhuan, Yang Jianhong

Chinese Pharmaceutical Affairs ›› 2022, Vol. 36 ›› Issue (6) : 637-643.

Chinese Pharmaceutical Affairs ›› 2022, Vol. 36 ›› Issue (6) : 637-643. DOI: 10.16153/j.1002-7777.2022.06.006

Research IV on Pharmacovigilance and Risk Control During Clinical Trials of New Drugs: A Study on Regulatory Requirements for Periodic Safety Report in Clinical Trials

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2022, 36(6): 637-643 https://doi.org/10.16153/j.1002-7777.2022.06.006

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}

Accesses

Citation

Detail
Sections
Recommended
京ICP备17052540号-4
Copyright © Chinese Pharmaceutical Affairs, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉